Dr. Rampal on the Importance of Risk Stratification in Myelofibrosis


In Partnership With:

Raajit K. Rampal, MD, PhD, discusses the importance of risk stratification in myelofibrosis.

Raajit K. Rampal, MD, PhD, hematologic oncologist, Memorial Sloan Kettering Cancer Center, discusses the importance of risk stratification in myelofibrosis.

Risk stratification with available scoring systems can inform whether a patient with myelofibrosis will derive a sustained response with JAK inhibitors, Rampal says. Additionally, risk stratification can provide insight into how likely a patient is to have short-term disease progression. These factors may inform treatment selection. For example, patients with transplant-eligible myelofibrosis might be considered for transplant earlier based on the scoring system criteria, Rampal explains.

Notably, risk stratification can also indicate whether a patient should be considered for a clinical trial. The limitations of JAK inhibitors are known, so some patients with a high risk of disease progression on JAK inhibitors could be considered for an investigational strategy earlier in their disease course based on scoring system criteria, Rampal concludes.

Related Videos
Catherine C. Coombs, MD, associate clinical professor, medicine, University of California, Irvine School of Medicine
Naomi Adjei, MD, MPH, MSEd, gynecologic oncology fellow, The University of Texas MD Anderson Cancer Center
John M. Kirkwood, MD, Distinguished Service Professor of Medicine, Sandra and Thomas Usher Professor of Medicine, Dermatology & Translational Science, coleader, Melanoma and Skin Cancer Program, Division of Hematology/Oncology, the University of Pittsburgh
Nizar M. Tannir, MD, FACP, professor; Ransom Horne, Jr. Professor for Cancer Research, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center
William B. Pearse, MD
Daniel Olson, MD
Nan Chen, MD
Robert Dreicer, MD, director, Solid Tumor Oncology, Division of Hematology/Oncology, professor of Medicine and Urology, deputy director, University of Virginia Cancer Center
Akriti Jain, MD
Samer A. Srour, MB ChB, MS